In September 2013, the FDA introduced new labeling guidelines for extensive acting and prolonged release opioids demanding companies to eliminate reasonable pain as sign for use, rather stating the drug is for "discomfort significant adequate to need every day, all over-the-clock, long-term opioid procedure".In many cases, insurance coverage firms